Mineralys Reports Positive Results from Phase III Lorundrostat Trial for Hypertension

Mineralys Therapeutics announced promising outcomes from its pivotal Phase III Launch-HTN trial evaluating lorundrostat, an oral aldosterone synthase inhibitor, in patients with uncontrolled or resistant hypertension (uHTN/rHTN). The global, double-blind study enrolled over 1,000 subjects on two to five antihypertensive medications.

Participants received placebo, lorundrostat 50mg once daily, or 50mg escalating to 100mg at week six. The primary endpoint—change in automated office systolic blood pressure (AOBP) from baseline—was met with a 16.9 mmHg reduction at six weeks and a 19 mmHg decrease by week 12 versus placebo.

Lorundrostat showed a favorable safety and tolerability profile, with reversible serum electrolyte effects and no cortisol suppression. The trial mirrored real-world settings by allowing participants to continue their existing treatments. Mineralys aims to advance lorundrostat as a targeted option for hypertension and related conditions.

28-05-2025